Isomorphic Labs IPO
Isomorphic Labs is an AI-driven drug discovery company spun out from DeepMind, Alphabet's AI research division. The company applies advanced artificial intelligence and machine learning techniques to accelerate the discovery and development of new medicines.
What We Know
Isomorphic Labs was founded in 2021 as a subsidiary of Alphabet Inc., leveraging DeepMind's AI expertise for drug discovery. The company has formed significant partnerships, including multi-billion dollar deals with pharmaceutical giants like Eli Lilly and Novartis to apply AI to drug development. As an Alphabet subsidiary, the company's path to public markets would likely involve a spinoff from its parent company, but no such plans have been announced. The company continues to advance its AI platform and pharmaceutical partnerships while remaining under Alphabet's ownership.
Frequently Asked Questions
Has Isomorphic Labs had an IPO?
No, Isomorphic Labs has not had an IPO and operates as a subsidiary of Alphabet Inc. The company has not announced any plans for independent public trading.
When is the Isomorphic Labs IPO date?
No IPO date has been announced for Isomorphic Labs. As an Alphabet subsidiary, any public market entry would likely require a spinoff, with no confirmed timeline. Sign up for alerts to stay informed.
How can I buy Isomorphic Labs stock?
Isomorphic Labs stock is not directly available for purchase as it operates as an Alphabet subsidiary. Investors can gain exposure through Alphabet shares (GOOGL/GOOG). Sign up for alerts to stay informed.
Stay Updated on the Isomorphic Labs IPO
Get real-time alerts when Isomorphic Labs files for an IPO, prices shares, or begins trading.
Get IPO Alerts